EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7 ‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity

Myung Jin Lee iD, Yoon Seon Lee iD, Joo-Cheol Park iD, Hyun Chul Kim iD, So Hyun Park, Howard Lee iD, Won Jun Shon iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70326 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Myung Jin Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Conservative Dentistry, School of Dentistry and Institute of Oral Bioscience, Jeonbuk National University, Jeonju, Republic of Korea. Hauptthemen laut MEDLINE: Dentin Sensitivity, Peptides, Dentin Desensitizing Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, Clinical Research Support Program at Seoul National University Dental Hospital, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dentin hypersensitivity is characterized by transient, sharp pain resulting from dentin exposure due to enamel or cementum loss. Current treatments, which primarily focus on superficial tubule occlusion or nerve desensitization, provide only temporary relief. Copine7 (CPNE7) induces odontoblast differentiation and physiologic dentin regeneration, enabling biological dentin sealing and presenting a novel therapeutic approach. This study reports the first‐in‐human results of a randomized, double‐blind, dose‐escalation phase 1/2a clinical trial evaluating the safety, tolerability, preliminary efficacy, and pharmacokinetics of the CPNE7‐derived functional peptide (selcopintide) in patients with dentin hypersensitivity. In Part A (Single Ascending Dose, SAD), 24 participants received a single topical application of selcopintide at ascending doses (2.5, 5, and 10 μg/tooth) in a 6:2 randomization ratio (treatment: placebo). In Part B (Multiple Ascending Dose, MAD), 16 participants received three topical applications (5 and 10 μg/tooth) over 15 days (day 1, 8, and 15; visits 2–4) with the same randomization ratio. Efficacy endpoints were assessed by changes in cold water, evaporative air, and tactile sensitivity. In Part B, the 10 μg selcopintide group demonstrated statistically significant reductions from the baseline across all three measures ( p < 0.05), with a mean decrease of −23.2 ± 19.4 mm in VAS, the primary efficacy endpoint. All doses were well tolerated, with no serious adverse events and no detectable systemic absorption of selcopintide. These findings support the safety, tolerability, and preliminary efficacy of selcopintide as a novel therapeutic candidate for the treatment of dentin hypersensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dentin SensitivityPeptidesDentin Desensitizing AgentsHumansMaleFemaleMiddle AgedAdultDouble-Blind MethodTreatment OutcomeYoung AdultAgedDose-Response Relationship, Drug

Stichwörter der Autor:innen

clinical trialsefficacypharmacokineticssafetytolerance

Substanzen

PeptidesDentin Desensitizing Agents

Autor:innen und Institutionen

  • Department of Conservative Dentistry, School of Dentistry and Institute of Oral Bioscience, Jeonbuk National University, Jeonju, Republic of Korea.
  • Research Institute of Clinical Medicine, of Jeonbuk National University, Jeonju, Republic of Korea.
  • Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.
  • Department of Conservative Dentistry, Dental Research Institute and School of Dentistry, Seoul National University, Seoul, South Korea.
  • Department of Oral Histology-Developmental Biology, Dental Research Institute and School of Dentistry, Seoul National University, Seoul, South Korea.
  • Regenerative Dental Medicine R&D Center, HysensBio Co., Ltd., Seoul, Republic of Korea.

ORCID-Profile: Myung Jin Lee, Yoon Seon Lee, Joo-Cheol Park, Hyun Chul Kim, Howard Lee, Won Jun Shon

Förderung

  • Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
  • Clinical Research Support Program at Seoul National University Dental Hospital
  • Korea Health Industry Development Institute

Zitieren

APA

Lee, M. J., Lee, Y. S., Park, J. C., Kim, H. C., Park, S. H., Lee, H., & Shon, W. J. (2025). First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7 ‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity. Clinical and Translational Science. https://doi.org/10.1111/cts.70326

Vancouver

Lee MJ, Lee YS, Park JC, Kim HC, Park SH, Lee H, et al. First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7 ‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity. Clinical and Translational Science. 2025. doi:10.1111/cts.70326

BibTeX
@article{Lee2025,
  author = {Lee, Myung Jin and Lee, Yoon Seon and Park, Joo-Cheol and Kim, Hyun Chul and Park, So Hyun and Lee, Howard and Shon, Won Jun},
  title = {First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7 ‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70326}
}
Kostenlos starten →